Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study

• Published in: Journal of clinical oncology Vol. 5; no. 11; p. 1791
• Main Authors: Alberts, D S, Kronmal, R, Baker, L H, Stock-Novack, D L, Surwit, E A, Boutselis, J G, Hannigan, E V
• Format: Journal Article
• Language: English
• Published: United States 01-11-1987
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bleomycin - adverse effects; Bleomycin - therapeutic use; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - mortality; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Drug Evaluation; Female; Humans; Middle Aged; Mitomycin; Mitomycins - adverse effects; Mitomycins - therapeutic use; Neoplasm Metastasis; Random Allocation; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - mortality; Vincristine - adverse effects; Vincristine - therapeutic use
• ISSN: 0732-183X
• DOI: 10.1200/jco.1987.5.11.1791

Cisplatin has proven to be the most active single agent in the treatment of metastatic and recurrent squamous cell cancer of the cervix. In a previous southwest Oncology Group (SWOG) pilot study, the addition of cisplatin to a mitomycin-C, vincristine, and bleomycin (MVB) regimen resulted in a relatively high percentage of durable complete responses. To gain more experience with cisplatin-based chemotherapy regimens, the SWOG initiated a phase II randomized trial of cisplatin, mitomycin-C plus cisplatin (MC), and MVB plus cisplatin (MVBC) in 119 patients with advanced squamous cell cancer of the cervix and no prior chemotherapy exposure. Because of slow patient accrual early in the trial, the cisplatin arm was discontinued. Five patients were declared ineligible according to protocol criteria. The three treatment groups were relatively well matched for age, prior radiation exposure, and sites of measurable disease. The overall objective response rates for cisplatin, MC, and MVBC treated patients were 33%, 25%, and 22%, respectively. Median response durations were greater than 6 months. Median survival durations associated with cisplatin, MC, and MVBC treatment were 17.0, 7.0, and 6.9 months, respectively. There were no drug-related deaths. Severe or life-threatening leukopenia and thrombocytopenia were observed in 18% to 24% of patients treated with MVBC and MC, but in none of those receiving cisplatin alone. We conclude that the low response rates and short durations of both response and survival observed in patients randomized to the two chemotherapy combinations suggest that only enhanced toxicity was gained through the addition of mitomycin-C or MVB to cisplatin in patients with advanced cervix cancer.